This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

Data availability
Raw data were generated at the University of Texas MD Anderson Cancer Center. Derived data supporting the findings of this study are available from the corresponding author JLR upon reasonable request.
References
Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, et al. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study. Leukemia. 2023;37:433–40. https://doi.org/10.1038/s41375-022-01780-1.
Bachy E, Camus V, Thieblemont C, Sibon, D, Casasnovas, R, Ysebaert, L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: Results of the Ro-CHOP Phase III study (Conducted by LYSA). J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.01815.
Valdez BC, Li Y, Murray D, Brammer J, Liu Y, Hosing C, et al. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 2016;7:63829–38.
Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharm Sci. 2006;27:438–46.
Valdez BC, Hassan M, Andersson BS. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp Hematol. 2017;52:65–71.
Author information
Authors and Affiliations
Contributions
JLR, BSA, and YN contributed to writing in each section of the article. BV and BSA have made a substantial contribution to the concept and design of the article and research models in the laboratory.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ramdial, J.L., Valdez, B.C., Andersson, B.S. et al. Romidepsin antagonism with CHOEP. Leukemia (2023). https://doi.org/10.1038/s41375-023-01873-5
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41375-023-01873-5